Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vartumab F8scFv
- Development stage
- Unknown
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vartumab F8scFv is a zirconium-89-radiolabeled single-chain variable fragment (scFv) antibody fragment developed by VAR2 Pharmaceuticals. It targets oncofetal Chondroitin Sulfate (ofCS), a tumor-specific glycosaminoglycan that is highly expressed in a wide range of solid tumors but absent from normal tissues. The agent is being evaluated in the Phase 0 VARTUTRACE trial (NCT06645808) as a PET/CT molecular imaging tracer to assess tumor targeting, biodistribution, and pharmacokinetics. This microdosing study aims to validate ofCS as a target for future therapeutic applications, specifically Vartumab-based antibody-drug conjugates (ADCs).
- Other names
- 89Zr-Vartumab F8scFvzirconium-89-radiolabeled Vartumab F8scFvzirconium89-radiolabeled Vartumab F8scFvzirconium 89-radiolabeled Vartumab F8scFv
02
Targets
ofCS (Oncofetal chondroitin sulfate)
Beyond the preview
Go deeper on Vartumab F8scFv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vartumab F8scFv.